Results 21 to 30 of about 387,985 (305)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis

open access: yesJournal of Dermatological Treatment, 2023
Background Clinical trials have shown promising results for interleukin-23 inhibitors in the treatment of psoriasis. The drugs have been used in clinical practice since 2017.
Cathrine Dawn Büttner Elgaard   +2 more
doaj   +1 more source

Overcoming steroid resistance in T cell acute lymphoblastic leukemia [PDF]

open access: yes, 2016
In a Perspective, Pieter Van Vlierberghe and Steven Goossens discuss Meijerink and colleagues' findings on steroid resistance in pediatric T cell acute lymphoblastic ...
Goossens, Steven   +1 more
core   +3 more sources

AUTOINFLAMMATORY DISEASES IN RHEUMATOLOGY: RUSSIAN EXPERIENCE

open access: yesНаучно-практическая ревматология, 2016
Autoinflammatory diseases (AIDs) are characterized by periodic, sometimes self-limiting attacks that appear as fever and clinical symptoms resembling rheumatic ones, in the absence of autoimmune or infectious diseases.
S. O. Salugina   +4 more
doaj   +1 more source

IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus

open access: yesFrontiers in Pharmacology, 2017
Diabetes mellitus (DM) is a chronic disease that affects nowadays millions of people worldwide. In adults, type 2 diabetes mellitus (T2DM) accounts for the majority of all diagnosed cases of diabetes.
Concepción Peiró   +8 more
doaj   +1 more source

Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway [PDF]

open access: yes, 2003
Objective. Erythropoietin (EPO) is a key regulator of erythropoiesis, playing a role in both the proliferation and differentiation of erythroid cells.
Bieber   +36 more
core   +1 more source

Immunomodulatory drug therapy for the disease caused by SARS-CoV-2 infection (COVID-19)

open access: yesAlʹmanah Kliničeskoj Mediciny, 2020
This systematic review focuses on the state-of-the-art pharmacotherapy of immune disorders in the novel coronavirus infection (COVID-19), leading to a cytokine storm and uncontrolled inflammatory response that causes severe tissue damage and multiple ...
D. E. Karateev, E. L. Luchikhina
doaj   +1 more source

Emerging targets in human lymphoma: targeting the MYD88 mutation [PDF]

open access: yes, 2016
B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link ...
Horikawa, Keisuke   +2 more
core   +1 more source

Comparative analysis of IL-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patients with various solid tumors

open access: yesМедицинская иммунология, 2021
The action of checkpoint inhibitors is based on activation of T cell antitumor immunity, and, therefore, the search for markers of lymphocyte functional activity before starting the therapy is highly relevant.
R. V. Orlova   +5 more
doaj   +1 more source

Constitutive cytoplasmic localization of p21Waf1/Cip1 affects the apoptotic process in monocytic leukaemia [PDF]

open access: yes, 2003
In the present study, we analysed the expression and localization of p21Waf1/Cip1 in normal and malignant haematopoietic cells. We demonstrate that in normal monocytic cells, protein kinase C (PKC)-induced p21 gene activation, which is nuclear factor-κB (
A de Thonel   +44 more
core   +3 more sources

A clinical case of adult-onset Still's disease resistant to therapy with tumor necrosis factor-alpha inhibitors and interleukin-6 inhibitors

open access: yesСовременная ревматология, 2019
The basis of the clinical picture of adult-onset Still's disease is a triad of symptoms, includingfever, arthralgia/arthritis, and characteristic rash called «Still rash».
R. R. Samigullina   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy